SAM
VYGR icon

Smartleaf Asset Management’s Voyager Therapeutics VYGR Stock Holding History

Smartleaf Asset Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-835
Closed -$3.05K – 2985
2025
Q1 		$3.05K Buy
+835
New +$3.9K ﹤0.01% 2364

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Smartleaf Asset Management's VYGR Position: Q2 2025 in Review

Smartleaf Asset Management sold out of Voyager Therapeutics (VYGR) in Q2 2025, closing a stake of 835 shares — an estimated $3.05K sold.

Smartleaf Asset Management first reported a position in VYGR in Q1 2025 and held it in 1 quarter. The position peaked at $3.05K in Q1 2025. 112 funds tracked by Wall St. Rank hold VYGR as of Q2 2025.

  • Smartleaf Asset Management reported no remaining Voyager Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Smartleaf Asset Management sold 835 Voyager Therapeutics shares in Q2 2025, an estimated $3.05K.
  • Smartleaf Asset Management first reported a position in Voyager Therapeutics in Q1 2025 and held it in 1 quarter.
  • Smartleaf Asset Management's Voyager Therapeutics position peaked at $3.05K in Q1 2025.
  • 112 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2025.

Based on Smartleaf Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.